Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
100 participants
INTERVENTIONAL
2022-10-01
2023-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Restarting Anticoagulation After Traumatic Intracranial Hemorrhage
NCT04229758
Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)
NCT06433622
Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas
NCT05491356
Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.
NCT02684812
Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury
NCT00755209
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 week restart
Restart of mono or dual antiplatelet therapy one week post injury in TICrH patients
Timing/1 week
Time of restart of antiplatelet therapy is one week after injury
3 week restart
Usual Care for restart of mono or dual antiplatelet therapy after TICrH at clinician's discretion
Timing/3 weeks
Time of restart of antiplatelet therapy is left to treating clinician discretion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Timing/1 week
Time of restart of antiplatelet therapy is one week after injury
Timing/3 weeks
Time of restart of antiplatelet therapy is left to treating clinician discretion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. History of stroke, vascular stent or coronary or peripheral arterial disease as indication for antiplatelet \*Restarting dual platelet therapy requires one of the following indications: 1) Acute myocardial infarction in the last year; 2) Coronary stent in the last year; 3) Non-cardioembolic stroke in the last 21 days (with switch to monotherapy at 21 days post stroke) 4) Peripheral arterial stent in the past month (with switch to monotherapy at one month post stent placement).
Exclusion Criteria
2. Physician plan to start/restart anticoagulant therapy during trial period
3. Abbreviated Injury Scale other than head \>3
4. Pregnancy
5. Inability to understand need for adherence to study protocol
6. Any active pathological bleeding (no acute blood on most recent CT)
7. Hypersensitivity to drug or other label contraindication
8. Any bleeding that the investigator deems unsafe to restart at 1 week post injury
9. Inability to swallow
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Truman J Milling Jr
Research Director SDMS Stroke Institute
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UT 101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.